INTRODUCTION: Pressure ulcers (PU) are one of the main challenges for nursing in our country. Wound bed preparation and the TIME algorithm provide essential tools for adequately treating these lesions. However, these wounds tend to become chronic due to the bacterial load in their bed. It is now known that bacteria can form complex and diverse structures, named as biofilm, which are difficult to diagnose and much more resistant to antimicrobial action.
Controlling these biofilms is crucial to create the optimal conditions for wound healing. Currently, it is believed that biofilms are present in 60-100% of chronic wounds. Therefore, more studies are needed to evaluate the efficacy of different antimicrobial agents on these structures.
OBJECTIVE: To determine the efficacy of a gel containing polyhexanide and biguanide, alone or in combination with alginate with or without silver, in preventing biofilm in PU, in terms of healing at 4 weeks.
METHODOLOGY: Multicenter clinical trial with a 2x2 factorial design, conducted with patients from Alcoy with category II and III PUs that meet the inclusion and exclusion criteria. A sample of 140 participants is estimated, distributed into four groups of 35 patients. The interventions that will be carried out will be: application of Prontosan gel® and Aquacel Ag+®; Aquacel Ag+®; control group; Prontosan gel®. Data on wound evolution will be collected using RESVECH 2.0. Descriptive statistical analysis and hypothesis testing will be performed.

Start Date30 Jan 2026

Sponsor / Collaborator-

NCT07195864

/ RecruitingNot Applicable

Retrospective Chart Review of Patients With Acanthamoeba Keratitis Who Have Received 0.8 mg/mL Polihexanide as Part of the "Medicines in Special Situations" (Medicamentos en Situaciones Especiales) Program in Spain.

The study will be a multicentric, retrospective, non-interventional medical chart review of patients with AK who initiated a treatment with 0.8 mg/ml polihexanide as part of the Spanish Medicines in Special Situations program, whether they fully completed the treatment or not.
Baseline date is defined as the date of 0.8 mg/ml polihexanide initiation. The Study Period for each patient will be considered the period from the baseline to the conclusion of the treatment.

Start Date30 Oct 2025

Sponsor / Collaborator

SIFI SpA

NCT06633588

/ RecruitingPhase 4IIT

Surgical Prophylaxis: Assessing Decolonization Efficacy of Polyhexanide Versus Mupirocin and Chlorhexidine in Decolonizing Staphylococcus Aureus Preoperatively in Elective Spine Surgery (SPADE): A Pilot Randomized Controlled Trial

This pilot randomized controlled trial evaluates the feasibility, tolerability, and preliminary efficacy of a decolonization regimen using polyhexanide in reducing Staphylococcus aureus colonization in the preoperative phase of elective spine surgery, compared to the standard mupirocin and chlorhexidine regimen. The trial involves 24 participants randomized into two groups: one receiving polyhexanide and the other receiving mupirocin and chlorhexidine. The primary outcome is the randomization rate, with secondary outcomes including other feasibility outcomes, tolerability, and efficacy measures such as the reduction in S. aureus colony-forming units (CFUs) and changes in the nasal and skin microbiome composition.

Start Date01 May 2025

Sponsor / Collaborator-

100 Clinical Results associated with Polihexanide

100 Translational Medicine associated with Polihexanide

100 Patents (Medical) associated with Polihexanide

786

Literatures (Medical) associated with Polihexanide

01 Dec 2026·PARASITOLOGY RESEARCH

Multidrug-resistant Acanthamoeba keratitis caused by the T4 Genotype: A case report

Article

Author: Kazemirad, Elham ; Atighehchian, Mehrnaz ; Kasiri, Maryam ; Zarei-Ghanavati, Mehran ; Latifi, Alireza

This report describes the case of a 28-year-old woman, who presented with a two-week history of severe ocular pain and photophobia in her right eye. She was a soft contact lens wearer with no history of ocular trauma or systemic illness. Ophthalmic examination revealed conjunctival hyperemia, epithelial irregularities, and a developing ring-shaped stromal infiltrate. In vivo confocal microscopy demonstrated double-walled hyperreflective cysts, and culture followed by PCR and sequencing confirmed the presence of Acanthamoeba T4 genotype. Despite intensive treatment with topical polyhexamethylene biguanide, chlorhexidine, propamidine, and voriconazole, as well as oral miltefosine, the infection progressed, leading to stromal necrosis. The patient underwent two therapeutic penetrating keratoplasties; however, the disease continued to advance, eventually resulting in phthisis bulbi and permanent vision loss. This case highlights the potential for aggressive, clinically refractory Acanthamoeba keratitis caused by the T4 genotype, emphasizing the importance of early diagnosis, vigilant monitoring, and timely surgical intervention in resistant cases.

01 Feb 2026·VETERINARY JOURNAL

Dog- to- dog bite wound management – Comparison of the antiseptic efficacy of polyhexanide and hypochlorous acid with regard to reducing the use of antibiotics: A randomized clinical trial

Article

Author: Reese, S ; Wolf, G ; Meyer-Lindenberg, A ; Peters, M ; Eberle, D

Therapy of dog bite wounds often includes empirical usage of antibiotics. This prospective clinical study aimed to compare the efficacy of polyhexanide and hypochlorous acid in reducing bacterial wound bio-burden and preventing the necessity for prophylactic antibiotics and to monitor the prevalence of multidrug- resistant bacteria. Thirty-four dogs with 51 bite wounds were randomly assigned to one of the treatment groups. Wounds were surgically debrided and treated with polyhexanide or hypochlorous acid. Swabs for culturing were taken three times: before and directly after debridement and directly after lavage. Veterinary patients were further divided into post-surgery care with and without prophylactic antibiotics. Wound healing until suture removal was monitored. Data were analyzed using a generalized linear model for ordinal data. Positive bacterial culture results after the first swab were obtained in 82.4 % wounds. Staphylococcus pseudintermedius was overrepresented in wounds, which later on developed complications. Neisseria species and streptococci species were overrepresented in cases of delayed wound closure. In 41.2 % of wounds multi-drug resistant bacteria could be detected. No negative effect of occurrence of multi-drug resistant bacteria on wound healing was observed. None of the compared antiseptics showed a significantly better wound decontamination. No superior antiseptic was found for wound lavage. Hypochlorous acid-based antiseptics provide the practical advantage of a shorter contact time. Prophylactic antibiotics should always be considered in severe dog bite wounds and might not be needed in low grade bite wounds.

07 Jan 2026·JAC-Antimicrobial Resistance

Molecular mechanisms of disinfectant resistance in Klebsiella pneumoniae

Article

Author: Skipp, Paul ; Noel, Daniel J ; Keevil, C William ; Nicholas, Benjamin I ; Wilks, Sandra A ; Bailey, Alistair

Abstract:

Objectives:

Chemical disinfectants are critical for infection control in healthcare environments and beyond, as exemplified by their vital role during the COVID-19 pandemic. Despite research repeatedly demonstrating that bacteria can develop adaptations that mitigate the efficacy of chemical disinfectants, the underlying molecular mechanisms remain poorly characterized. This study investigates the mechanisms that underpin resistance demonstrated by disinfectant-adapted Klebsiella pneumoniae NCTC 13443 samples.

Methods:

Resistant samples have previously undergone long-term in vitro adaptation via serial passage in increasing concentrations of common disinfectants benzalkonium chloride (BAC), didecydimethylammonium chloride (DDAC), polyhexamethylene biguanide (PHMB), chlorocresol or bronopol. A multi-omics approach was used to conduct in-depth molecular analyses of the adaptations that contribute to resistance.

Results:

K. pneumoniae adaptation to BAC, DDAC and PHMB was associated with the modification of lipid A causing the reduction of the net-negative charge of the outer surface, lowering the affinity of cationic disinfectants. This mechanism is also used for polymyxin and colistin resistance, highlighting a potential cross-resistance risk. Chlorocresol-adapted K. pneumoniae samples demonstrated increased expression of efflux pumps and expression changes linked to biofilm formation. Bronopol resistance was associated with promoting biofilm formation and increased thioredoxin expression to alleviate oxidative stress. Results indicate the potential role of N-ethylmaleimide reductase NemA in bronopol resistance via enzymatic degradation.

Conclusions:

These findings provide novel insights into how causative pathogens of healthcare-associated infections can adapt to and mitigate the effectiveness of common chemical disinfectants that are relied on globally every day as a critical infection control measure.

News (Medical) associated with Polihexanide

24 Sep 2025

·www.globenewswire.com

Dimora PHMB Skin and Wound Cleanser - Gentle for Kids, Trusted by Parents

Dimora PHMB Skin and Wound Cleanser: Gentle for Kids, Trusted by ParentsSAN FRANCISCO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Dimora Medical is proud to introduce its newest innovation, the Dimora PHMB Skin and Wound Cleanser. Designed with children’s needs in mind, this product offers a gentle, odorless alternative to traditional wound cleansers. Free from stinging sensations and harsh chemical smells, it helps create a more comfortable experience for both kids and caregivers. At the heart of the cleanser is PHMB, a trusted antibacterial ingredient that effectively protects against bacteria while being mild on the skin. Safe for use on minor cuts, scrapes, and abrasions, it’s an ideal solution for everyday home wound care. At Dimora Medical, the goal has always been simple: to make home care easy for families. With 34 years of experience in medical supplies, the team focuses on creating practical solutions that help people handle home wound care with confidence. The PHMB Skin and Wound Cleanser continues this approach. Suitable for everyday family use, and gentle enough for children over the age of three, it provides an easy, comfortable way to clean minor cuts and scrapes. View the Details Here A Gentle Cleanser for Life’s Little Ouches If you’ve got young kids at home, you know that bumps, scrapes, and little cuts are just part of growing up—whether it’s a tumble at the playground, a scraped knee from running around outside, or a nick from a favorite toy. These small injuries can feel like a big deal to little ones, and sometimes just as stressful for parents. That’s why having a wound cleanser that’s both gentle and effective really matters. Dimora PHMB Skin and Wound Cleanser was created for exactly these situations. Its key ingredient, PHMB (polyhexamethylene biguanide), is proven safe and gentle enough for children. Unlike alcohol, it doesn’t sting on contact, so kids won’t feel unnecessary pain. Its mildness is trusted worldwide—the same ingredient is used in contact lens solutions, where it touches delicate eye tissue daily. At the same time, PHMB provides fast, broad-spectrum antibacterial protection, helping prevent infection while keeping care stress-free. Because it’s odorless, the cleanser avoids the sharp chemical smell often associated with products like hypochlorous acid. This makes wound care less intimidating, reducing children’s fear and resistance. The precision spray nozzle adds to the ease of use. It directs a steady, gentle stream that rinses away dirt without irritating the wound, and the one-handed design makes it practical whether at home, outdoors, or on the go. Effective Protection, Without the Sting Treating small wounds shouldn’t have to mean choosing between comfort and protection. With Dimora PHMB Skin and Wound Cleanser, families get both. Its clinically trusted formula defends against a wide range of bacteria while staying gentle enough for children’s sensitive skin. Unlike harsh antiseptics that sting or leave behind strong odors, this cleanser keeps the experience calm and cooperative, helping kids feel reassured and parents confident. The result is reliable wound care that fits seamlessly into everyday family routines—without the stress that often comes with treatment. Engineered for Real-Life Family Moments Dimora’s latest product is not just clinically sound—it’s thoughtfully adapted for real-life scenarios. Whether it’s cleaning up a scraped knee after a soccer game, rinsing a small cut from a schoolyard fall, or addressing minor abrasions during a family camping trip, the PHMB cleanser is built to be a reliable companion in every parent’s first aid kit. The Dimora PHMB Skin and Wound Cleanser stays effective for up to eight weeks after opening, making it a practical choice for everyday use without unnecessary waste. For a limited time, it’s available at a special launch price of $17.99 (regularly $19.99), giving families an affordable way to upgrade their home first-aid kit. Now available on Amazon and the official Dimora website, this gentle, child-friendly cleanser is a smart addition to any household. Give your family the care they deserve—order now and be ready for life’s little accidents. A Brand Built on Simplicity, Care, and Everyday Confidence The launch of the Dimora PHMB Skin and Wound Cleanser reflects more than just a new product—it represents the heart of Dimora’s mission: to make home care easy. With a strong foundation in medical expertise, Dimora focuses on designing wound care solutions that are simple to use and thoughtfully built for real-life situations. From a scraped knee at home to a schoolyard tumble, the brand’s goal is to empower caregivers—especially non-professionals—to respond with confidence and compassion. As Dimora continues to grow, its commitment remains the same: to develop versatile, effective, and family-friendly products that simplify care, reduce stress, and give caregivers more time to focus on what really matters—comfort, connection, and peace of mind. Contact: Kim Yin, contact@winnermedical.com

11 Jun 2025

·pipelinereview.com

SIFI merges into Faes Farma to become its ophthalmic franchise and expand international access to its portfolio and pipeline

CATANIA, Italy I June 10, 2025 I SIFI, a leading international ophthalmic company, today announced that its shareholders have signed an agreement, subject to conditions precedent, to sell 100% of SIFI shares to Faes Farma, a leading European pharmaceutical company listed on the Spanish stock exchange. The transaction validates SIFI’s unique business model centred around the consolidated pharmaceutical and surgical units, combined with the fast-growing contract manufacturing and rare diseases units. SIFI will enable Faes Farma to offer one of the most comprehensive ophthalmology portfolios in the industry, with a complementary geographic presence. The integration of SIFI and Laboratorios Edol, a leading Portuguese pharmaceutical recently acquired by Faes Farma, positions ophthalmology as a pivotal area for the combined entity (the “Group”), representing approximately 20% of its pro-forma revenue, and allows for further portfolio synergies. SIFI facilitates the Group’s entry into new high-growth regions in Europe, such as Italy, France, Romania, and Turkey, while bolstering the Group’s presence in others, such as Iberia, Mexico and Latin America. Furthermore, product integration should unlock cross-selling opportunities, improving growth and margins through operational and cost efficiencies. The Group will invest into the further development of Akantior (polihexanide 0.08%) into existing and new geographies, most notably in the USA, as well as the development of polihexanide into additional orphan indications. Akantior is approved by the European Medicines Agency (EMA) and United Kingdom’s Medicines & Healthcare products Regulatory Agency (MHRA) for the treatment of Acanthamoeba Keratitis (AK) in adults and children aged 12 and older. Akantior is the first and only approved therapy for AK anywhere in the world, addressing an ultra-rare, severe, and progressive corneal infection affecting approximately 3,000 patients annually in Europe and the United States. Launched in Germany in October 2024, pricing and reimbursement procedures are underway in other European countries. It is also in the pre-registration phase with the FDA (U.S. Food and Drug Administration) with orphan drug designation. Polihexanide will soon begin clinical development for Fungal Keratitis, after promising preclinical data and the granting of orphan drug designation in Europe and US. SIFI will continue to operate its two state-of-the-art plants in Aci S. Antonio, focused on the production of ophthalmic medications and intraocular lenses, leveraging on recently secured long-term contract manufacturing agreements, with significant recurring revenue potential. Additionally, SIFI’s facilities will optimize the Group’s industrial capabilities, enhancing operational efficiency. “Faes Farma shares similar values, culture and is highly complementary to our organization, which is set to become the pillar of the enlarged group’s ambitious strategy in ophthalmology, a therapeutic area where the SIFI brand is synonymous with quality, innovation and long-term commitment. This transaction represents a key milestone for our company and will accelerate growth, unlock synergies, and enhance long-term value for all stakeholders, first and foremost by expanding global access to the medicines and devices we provide for ophthalmic patients.”, stated Fabrizio Chines , CEO of SIFI. “We are impressed with the strength of SIFI’s business model and the capabilities of its management team. This transaction strengthens our position in ophthalmology, a therapeutic area with significant growth potential, and accelerates our international expansion with direct access to new markets in Europe. We look forward to working with Fabrizio Chines and SIFI’s management team to fulfill our commitment to an innovative and more global ophthalmic franchise, offering a broader range of solutions aligned with the needs of professionals and patients and our common ambitions.”, stated Eduardo Recoder de la Cuadra , CEO of Faes Farma. The transaction values SIFI at an upfront Enterprise Value equal to a double-digit multiple of 2024 EBITDA, plus earn-outs linked to certain regulatory and commercial milestones related to Akantior. The transaction is expected to close in the third quarter of 2025, subject to customary approval by competition and foreign investment authorities and the extraordinary shareholders’ meeting of Faes Farma, which is expected during July 2025. Evercore Partners International LLP (“Evercore”) and Mediobanca – Banca di Credito Finanziario S.p.A. (“Mediobanca”) are acting as exclusive financial advisor to SIFI’s shareholders (founding families and 21 Invest SGR S.p.A. on behalf of managed fund 21 Investimenti III (“21 Invest”)). Hogan Lovells Studio Legale (“Hogan Lovells”) is acting as legal advisor. J.P. Morgan SE (“JPM”) is acting as Faes Farma’s exclusive financial advisor and debt financing provider in connection with the transaction. Cuatrecasas Legal SLP (“Cuatrecasas”) and Chiomenti Studio Legale (“Chiomenti”) serve as legal advisor and Ernst & Young Servicios Corporativos S.L. (“EY”), Gide Loyrette Nouel (“Gide”), Wolf Theiss Rechtsanwälte GmbH & Co KG (“Wolf Theiss”) and A.T. Kearney as due diligence providers for Faes Farma. About SIFI SIFI is a leading international ophthalmic company headquartered in Italy, featuring an integrated business model from research and development to manufacturing and commercialization in both pharmaceutical and biomedical sectors. Founded in 1935, SIFI’s mission is to improve people’s lives through meaningful innovation in eye care. The company exports to more than 60 countries worldwide with a direct presence in major European markets, Mexico, and through joint ventures in China and the United Arab Emirates. For more information, visit www.sifigroup.com About Faes Farma Faes Farma is a company with more than 90 years of experience and a presence in more than 130 countries through marketed or licensed products. Faes combine passion, science, and innovation to transform people’s health. Faes research, produce, and market prescription drugs, healthcare products, and animal nutrition products, and we aspire to become a leading pharmaceutical group in excellence and innovation. At Faes Farma, people are guided by our values: offering top-quality solutions for health and well-being, with the patient as our priority; developing innovative products that adapt to society’s needs; and ensuring integrity, transparency, and commitment through responsible management and excellence. For more information, visit www.faesfarma.com SOURCE: Faes Farma

Orphan DrugDrug Approval

10 Jun 2025

·www.prnewswire.com

SIFI merges into Faes Farma to become its ophthalmic franchise and expand international access to its portfolio and pipeline

The transaction will enable strong commercial synergies, thanks to Faes Farma's presence in complementary markets and recent acquisition of Laboratorios Edol It enables funding further development of SIFI's portfolio, most notably Akantior in the USA SIFI's existing infrastructure, including its Aci S. Antonio facilities, will further expand under the combined entity CATANIA, Italy, June 10, 2025 /PRNewswire/ -- SIFI, a leading international ophthalmic company, today announced that its shareholders have signed an agreement, subject to conditions precedent, to sell 100% of SIFI shares to Faes Farma, a leading European pharmaceutical company listed on the Spanish stock exchange. The transaction validates SIFI's unique business model centred around the consolidated pharmaceutical and surgical units, combined with the fast-growing contract manufacturing and rare diseases units. SIFI will enable Faes Farma to offer one of the most comprehensive ophthalmology portfolios in the industry, with a complementary geographic presence. The integration of SIFI and Laboratorios Edol, a leading Portuguese pharmaceutical recently acquired by Faes Farma, positions ophthalmology as a pivotal area for the combined entity (the "Group"), representing approximately 20% of its pro-forma revenue, and allows for further portfolio synergies. SIFI facilitates the Group's entry into new high-growth regions in Europe, such as Italy, France, Romania, and Turkey, while bolstering the Group's presence in others, such as Iberia, Mexico and Latin America. Furthermore, product integration should unlock cross-selling opportunities, improving growth and margins through operational and cost efficiencies. The Group will invest into the further development of Akantior (polihexanide 0.08%) into existing and new geographies, most notably in the USA, as well as the development of polihexanide into additional orphan indications. Akantior is approved by the European Medicines Agency (EMA) and United Kingdom's Medicines & Healthcare products Regulatory Agency (MHRA) for the treatment of Acanthamoeba Keratitis (AK) in adults and children aged 12 and older. Akantior is the first and only approved therapy for AK anywhere in the world, addressing an ultra-rare, severe, and progressive corneal infection affecting approximately 3,000 patients annually in Europe and the United States. Launched in Germany in October 2024, pricing and reimbursement procedures are underway in other European countries. It is also in the pre-registration phase with the FDA (U.S. Food and Drug Administration) with orphan drug designation. Polihexanide will soon begin clinical development for Fungal Keratitis, after promising preclinical data and the granting of orphan drug designation in Europe and US. SIFI will continue to operate its two state-of-the-art plants in Aci S. Antonio, focused on the production of ophthalmic medications and intraocular lenses, leveraging on recently secured long-term contract manufacturing agreements, with significant recurring revenue potential. Additionally, SIFI's facilities will optimize the Group's industrial capabilities, enhancing operational efficiency. "Faes Farma shares similar values, culture and is highly complementary to our organization, which is set to become the pillar of the enlarged group's ambitious strategy in ophthalmology, a therapeutic area where the SIFI brand is synonymous with quality, innovation and long-term commitment. This transaction represents a key milestone for our company and will accelerate growth, unlock synergies, and enhance long-term value for all stakeholders, first and foremost by expanding global access to the medicines and devices we provide for ophthalmic patients.", stated Fabrizio Chines, CEO of SIFI. "We are impressed with the strength of SIFI's business model and the capabilities of its management team. This transaction strengthens our position in ophthalmology, a therapeutic area with significant growth potential, and accelerates our international expansion with direct access to new markets in Europe. We look forward to working with Fabrizio Chines and SIFI's management team to fulfill our commitment to an innovative and more global ophthalmic franchise, offering a broader range of solutions aligned with the needs of professionals and patients and our common ambitions.", stated Eduardo Recoder de la Cuadra, CEO of Faes Farma. The transaction values SIFI at an upfront Enterprise Value equal to a double-digit multiple of 2024 EBITDA, plus earn-outs linked to certain regulatory and commercial milestones related to Akantior. The transaction is expected to close in the third quarter of 2025, subject to customary approval by competition and foreign investment authorities and the extraordinary shareholders' meeting of Faes Farma, which is expected during July 2025. Evercore Partners International LLP ("Evercore") and Mediobanca - Banca di Credito Finanziario S.p.A. ("Mediobanca") are acting as exclusive financial advisor to SIFI's shareholders (founding families and 21 Invest SGR S.p.A. on behalf of managed fund 21 Investimenti III ("21 Invest")). Hogan Lovells Studio Legale ("Hogan Lovells") is acting as legal advisor. J.P. Morgan SE ("JPM") is acting as Faes Farma's exclusive financial advisor and debt financing provider in connection with the transaction. Cuatrecasas Legal SLP ("Cuatrecasas") and Chiomenti Studio Legale ("Chiomenti") serve as legal advisor and Ernst & Young Servicios Corporativos S.L. ("EY"), Gide Loyrette Nouel ("Gide"), Wolf Theiss Rechtsanwälte GmbH & Co KG ("Wolf Theiss") and A.T. Kearney as due diligence providers for Faes Farma. About SIFI SIFI is a leading international ophthalmic company headquartered in Italy, featuring an integrated business model from research and development to manufacturing and commercialization in both pharmaceutical and biomedical sectors. Founded in 1935, SIFI's mission is to improve people's lives through meaningful innovation in eye care. The company exports to more than 60 countries worldwide with a direct presence in major European markets, Mexico, and through joint ventures in China and the United Arab Emirates. For more information, visit About Faes Farma Faes Farma is a company with more than 90 years of experience and a presence in more than 130 countries through marketed or licensed products. Faes combine passion, science, and innovation to transform people's health. Faes research, produce, and market prescription drugs, healthcare products, and animal nutrition products, and we aspire to become a leading pharmaceutical group in excellence and innovation. At Faes Farma, people are guided by our values: offering top-quality solutions for health and well-being, with the patient as our priority; developing innovative products that adapt to society's needs; and ensuring integrity, transparency, and commitment through responsible management and excellence. For more information, visit WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

AcquisitionDrug ApprovalOrphan Drug

100 Deals associated with Polihexanide

External Link

KEGG	Wiki	ATC	Drug Bank
D08399	Polihexanide	D08AC05	DB12277

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Acanthamoeba Keratitis	European Union	SIFI SpA	22 Aug 2024
Acanthamoeba Keratitis	Iceland	SIFI SpA	22 Aug 2024
Acanthamoeba Keratitis	Liechtenstein	SIFI SpA	22 Aug 2024
Acanthamoeba Keratitis	Norway	SIFI SpA	22 Aug 2024
Disinfectants	-	B. Braun Medical, Inc.	-
Wounds and Injuries	-	B. Braun Medical, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03274895 (Pubmed) Manual	Phase 3	Acanthamoeba Keratitis	127	PHMB 0.02%+ propamidine 0.1%	kgazupbser(foonqdgtaa) = wwifhwiioq xhlpsbwjbv (mbvavtksir ) View more	Positive	01 Mar 2024
				PHMB 0.08%+ placebo	kgazupbser(foonqdgtaa) = sblgulxnzh xhlpsbwjbv (mbvavtksir ) View more
NCT03274895 (The Orphan Drug for Acanthamoeba Keratitis (ODAK) Trial, CTgov)	Phase 3	Acanthamoeba Keratitis	135	placebo+PHMB 0.08% (PHMB 0.08% Plus Placebo)	tlsoezlrzy = zgefkprgjx ybcdfzqqee (eavivafwtk, xsjjkysgxx - quwonqclep) View more	-	02 Aug 2023
				Propamidine 0.1%+PHMB 0.02% (PHMB 0.02% Plus Propamidine 0.1%)	tlsoezlrzy = tgrlbzapyg ybcdfzqqee (eavivafwtk, uobvhcyhqh - gqzmbhauvq) View more
NCT03274895 (PRNewswire) Manual	Phase 3	Acanthamoeba Keratitis	135	Placebo+Polihexanide	ubxfqlqivl(vlrfinuilz) = mxttuqstwx fshbcmaajx (cpbcrvfkeq ) View more	Non-inferior	13 Oct 2022
				polihexanide+Polihexanide	ubxfqlqivl(vlrfinuilz) = celmbhorin fshbcmaajx (cpbcrvfkeq ) View more
NCT04055233 (RECIPE, Pubmed \| Ann Surg)	Phase 3	Surgical Wound Infection	456	Antiseptica (0.9% saline)	prcpsxdszm(wkfkqfgcuy) = mskpvlchby ebpntgymaq (eqtrwzzbhs )	Positive	01 Jul 2020
NCT02506257 (CTgov)	Phase 1	Acanthamoeba Keratitis	90	0.04% PHMB (0.04% PHMB)	zxkiepqjdt = teaxvtselr gvibppgmmw (umnjlqqybw, fmymrtptle - cqbdidirfb) View more	-	23 Nov 2016
				0.06% PHMB (0.06% PHMB)	zxkiepqjdt = rhqkytstaj gvibppgmmw (umnjlqqybw, ziwaujffyu - aspgmxlffc) View more
ODAK (ARVO2014)	Not Applicable	Acanthamoeba Keratitis	100	Polyhexamethylene biguanide (PHMB)	uamhfyzayw(oaxpbvmool) = vybzvoavny rsibguqojv (yjvhfzovac )	-	01 Apr 2014
				Combination therapy (PHMB and propamidine)	uamhfyzayw(oaxpbvmool) = rwehhvzkyc rsibguqojv (yjvhfzovac )
NCT01153620 (Lavasept 2, CTgov)	Phase 4	Wounds and Injuries	61	Lavasept 0.04% (Lavasept 0.04%)	oenrxgvbpd(unhdacrafv) = zuzvmwfnnt nvmyctggsp (reichysdud, 1.00) View more	-	29 Nov 2011
				Ringer's Solution (Ringer's Solution)	oenrxgvbpd(unhdacrafv) = ojnvjzdlsz nvmyctggsp (reichysdud, 0.85) View more
AAO2004	Not Applicable	-	43	Polyhexamethylene Biguanide (PHMB)	rpwaoekhwv(zygstjyzqo) = ikhuartcwi bvyxncdsya (wyrbysokwf ) View more	Negative	25 Oct 2004
				Chlorhexidine (CH)	rpwaoekhwv(zygstjyzqo) = ulqsczikfy bvyxncdsya (wyrbysokwf ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Polihexanide

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation